L-Theafetamine
Dual-acting prodrug combining a CNS stimulant (d-amphetamine) with L-theanine, designed for delayed CNS activation, neuromodulation, and reduced abuse liability.
Dual-acting prodrug combining a CNS stimulant (d-amphetamine) with L-theanine, designed for delayed CNS activation, neuromodulation, and reduced abuse liability.
(2S)-2-amino-5-(ethylamino)-N-(1-methyl-2-phenylethyl)-5-oxopentanamide
C16H25N3O2
291.195
Not assigned (novel compound)
0.69
8.23
15.73
Methodology: Values obtained using cheminformatics modeling
Results:
• logS (solubility) vs. pH: shows a rapid decrease in solubility between pH 6–8, plateauing beyond pH 9.
• logD (lipophilicity) vs. pH: increases from ~–2.5 at acidic pH to +0.5 at pH > 9.
• Interpretation: Compound is ionized in acidic environments (enhancing solubility) and becomes neutral/lipophilic in basic or physiological pH (enhancing absorption and enzymatic activation).
Conclusion:
These data support the compound’s function as a pH-responsive, amphiphilic prodrug designed for enzymatic hydrolysis into L-theanine and amphetamine.
Study of stimulant pharmacokinetics, dual-acting neuromodulatory prodrugs, CNS drug delivery.
Treatment of ADHD, narcolepsy, treatment-resistant depression, cognitive fatigue syndromes.
Prodrug design, novel CNS-active pharmaceutical development.
Standard laboratory protective equipment; gloves, lab coat, goggles.
Controlled environment, low humidity, room temperature; protect from light.
Novel stimulant; handle according to research chemical safety guidelines. Potential CNS stimulant effects.